Media-OutReach Newswire A Treatment Option for Metastatic Colorectal Cancer Patients with BRAFV600E Mutation in Singapore
Media-OutReach Newswire Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in highly debilitating autoinflammatory diseases